Hemab Therapeutics Holdings, Inc. COAG
42.81 USD -6.21 (-12.67%)
At closeNov 9, 2026, 4:44 PM EST
42.81 0.00 0.00%
After hours · Nov 9, 4:44 PM ET
42.63 Day range 50.22
24.98 52-week range 54.94
- YTD
- +25.91%
- 1 year
- +25.91%
News
benzinga.com Petrobras, TransDigm On Deck Tuesday As Oil Profits, Aerospace Demand Face Test Petroleo Brasileiro headlines Tuesday’s reports, with investors weighing whether strong production and operating performance can offset pressure on energy prices. TransDigm Group, Honda Motor, Sea,…
benzinga.com LifeSci Capital Initiates Coverage On Hemab Therapeutics Hldgs with Outperform Rating, Announces Price Target of $65 LifeSci Capital initiates coverage on Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Outperform rating and announces Price Target of $65.
benzinga.com Hemab Therapeutics Initiates SOLARA, Pivotal Phase 3 Trial Evaluating Sutacimig As Potential Prophylactic Treatment For People With Glanzmann Thrombasthenia Hemab’s first Phase 3 trial to evaluate once-weekly subcutaneous sutacimig in approximately 75 participants with Glanzmann thrombastheniaSingle-arm design with a 24-week run-in followed by 48 weeks…- benzinga.com Hemab Therapeutics To Present Two Presentations At American Society Of Hematology Annual Meeting Hemab Therapeutics (Nasdaq:COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today…
globenewswire.com Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and Exposition First clinical data for sutacimig in Factor VII deficiency (FVIID) shows multi-fold accumulation of endogenous FVII(a) with shortening of prothrombin time after a single subcutaneous dose in initial…
globenewswire.com Hemab Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 10, 2026 CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment…
benzinga.com JP Morgan Initiates Coverage On Hemab Therapeutics Hldgs with Overweight Rating, Announces Price Target of $70 JP Morgan analyst Joyce Zhou initiates coverage on Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Overweight rating and announces Price Target of $70.- benzinga.com Rodman & Renshaw Initiates Coverage On Hemab Therapeutics Hldgs with Buy Rating, Announces Price Target of $56 Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy rating and announces Price Target of $56.
benzinga.com Why Webuy Global Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket Shares of Webuy Global Ltd (NASDAQ:WBUY) rose sharply in pre-market trading. Webuy reported record preliminary unaudited travel bookings of around $4.76 million during the three-day NATAS Fair in…
benzinga.com Wedbush Maintains Outperform on Hemab Therapeutics Hldgs, Raises Price Target to $64 Wedbush analyst David Nierengarten maintains Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Outperform and raises the price target from $55 to $64.
benzinga.com HC Wainwright & Co. Maintains Buy on Hemab Therapeutics Hldgs, Raises Price Target to $60 HC Wainwright & Co. analyst Emily Bodnar maintains Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy and raises the price target from $52 to $60.- benzinga.com Hemab Therapeutics Hldgs Q2 EPS $(0.80) Misses $(0.52) Estimate Hemab Therapeutics Hldgs (NASDAQ:COAG) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.52) by 53.85 percent. This is a 93.8 percent increase over…
- benzinga.com Hemab Therapeutics Presents Clinical, Preclinical Data From Sutacimig In Glanzmann Thrombasthenia And Factor VII Deficiency At International Society On Thrombosis And Haemostasis 2026 Congress Hemab Therapeutics (Nasdaq:COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience, today…
benzinga.com Jefferies Maintains Buy on Hemab Therapeutics Hldgs, Raises Price Target to $47 Jefferies analyst Maury Raycroft maintains Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy and raises the price target from $39 to $47.
benzinga.com Hemab Advances Bleeding Disorder Pipeline Hemab reports new HMB-002 Von Willebrand disease data, and introduced HMB-003, targeting heavy menstrual bleeding.- benzinga.com CORRECTION: Wedbush Maintains Outperform on Hemab Therapeutics Hldgs, Raises Price Target To $55 Wedbush analyst David Nierengarten maintains Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Outperform and raises the price target from $42 to $55.
benzinga.com Wedbush Reiterates Outperform on Hemab Therapeutics Hldgs, Maintains $55 Price Target Wedbush analyst David Nierengarten reiterates Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Outperform and maintains $55 price target.- benzinga.com HC Wainwright & Co. Maintains Buy on Hemab Therapeutics Hldgs, Raises Price Target to $52 HC Wainwright & Co. analyst Emily Bodnar maintains Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy and raises the price target from $40 to $52.
benzinga.com Reported Sunday, Hemab Therapeutics Presents New HMB-002 Clinical Data Showing ≥2.4-Fold Dose-Dependent VWF And FVIII Increases In Von Willebrand Disease, Introduces HMB-003 For Heavy Menstrual Bleeding At ISTH 2026 Congress HMB-002 clinical data demonstrate proof of mechanism, with dose-dependent, greater than or equal to 2.4-fold peak increases in Von Willebrand Factor (VWF) and Factor VIII (FVIII), normalization of…- benzinga.com HC Wainwright & Co. Reiterates Buy on Hemab Therapeutics Hldgs, Maintains $40 Price Target HC Wainwright & Co. analyst Emily Bodnar reiterates Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy and maintains $40 price target.
- benzinga.com Hemab Therapeutics To Present Clinical And Preclinical Data From Multiple Blood Coagulation Programs At ISTH 2026 July 11-15 Presentation Highlights and Details – The abstracts are now available through the ISTH conference websiteSutacimigSutacimig showed sustained prophylaxis in GT (meaningful reduction in ATBR and…
benzinga.com This Charles River Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday Top Wall Street analysts upgraded MITT & MFA. See ratings & price targets for these stocks. Should you buy MFA?
benzinga.com This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday Top analysts changed outlook on top names. See all changes, including upgrades/downgrades/coverage initiations at Benzinga's analyst ratings page.- benzinga.com HC Wainwright & Co. Initiates Coverage On Hemab Therapeutics Hldgs with Buy Rating, Announces Price Target of $40 HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy rating and announces Price Target of $40.
- benzinga.com Wedbush Initiates Coverage On Hemab Therapeutics Hldgs with Outperform Rating, Announces Price Target of $42 Wedbush analyst David Nierengarten initiates coverage on Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Outperform rating and announces Price Target of $42.
benzinga.com Jefferies Initiates Coverage On Hemab Therapeutics Hldgs with Buy Rating, Announces Price Target of $39 Jefferies analyst Maury Raycroft initiates coverage on Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy rating and announces Price Target of $39.- benzinga.com Evercore ISI Group Initiates Coverage On Hemab Therapeutics Hldgs with Outperform Rating, Announces Price Target of $50 Evercore ISI Group analyst Cory Kasimov initiates coverage on Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Outperform rating and announces Price Target of $50.
benzinga.com This Avalyn Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Analysts have mixed views on AVLN stock.- benzinga.com Goldman Sachs Initiates Coverage On Hemab Therapeutics Hldgs with Buy Rating, Announces Price Target of $36 Goldman Sachs analyst Richard Law initiates coverage on Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy rating and announces Price Target of $36.
benzinga.com Earnings Scheduled For May 21, 2026 - benzinga.com Hemab Therapeutics Hldgs Q1 EPS $(23.98) Down From $(16.18) YoY Hemab Therapeutics Hldgs (NASDAQ:COAG) reported quarterly losses of $(23.98) per share. This is a 48.21 percent decrease over losses of $(16.18) per share from the same period last year.
benzinga.com Norwegian Cruise Line, Aura Biosciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session US stock futures lower, Dow futures down 200 points. Norwegian Cruise Line shares fall after Q1 results, cuts FY guidance. Other stocks also down.
benzinga.com Why eBay Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket eBay (NASDAQ: EBAY) rose sharply after GameStop (NYSE: GME) proposed to acquire it for $125/share, valuing GME at $55.5B. eBay shares jumped 8.1% to $112.50 in pre-market trading.